Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Dec;8(6):508-15.

A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy

R Shapiro  1 , M Jordan, V Scantlebury, C Vivas, J Fung, J McCauley, A Tzakis, P Randhawa, A J Demetris, W Irish, et al.
Affiliations
Clinical Trial

A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy

R Shapiro et al. Clin Transplant. 1994 Dec.

Abstract

Previous clinical evaluation of FK506 in renal transplantation has demonstrated equivalent patient and graft survival when compared with cyclosporine-based regimens. However, lower steroid and anti-hypertensive mediation requirements and lower serum cholesterol levels have been seen in patients receiving FK506. In August, 1991, a prospective, randomized trial was begun, comparing FK506/prednisone with FK506/azathioprine/prednisone. Two-hundred-and-four adults were entered into this trial between August 1, 1991, and October 11, 1992. The mean recipient age was 43.8 +/- 13.7 years, with a range of 17.6-78.0 years. Sixty-one (30%) recipients received a 2nd, 3rd or 4th transplant, while 35 (17%) had a PRA greater than 40% at the time of transplant. Thirty-three (16%) of the transplants were in recipients over 60 years of age, Thirteen percent of the kidneys were from living donors; 13% of the cadaveric kidneys were from pediatric donors less than 3 years of age and were transplanted en bloc. The mean cold ischemia time was 31.4 +/- 8.4 hours, and the mean donor age was 34 +/- 2.10 years, with a range from 4 months to 75 years. With a mean follow-up of 9 +/- 4 months, the 1-year actuarial patient survival is 93%; for the two-drug group it is 95%, and for the three-drug group it is 91% (p = NS). One-year actuarial graft survival is 86%; in the two-drug group it is 90%, while in the three-drug group it is 82% (p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient and graft survival.
See this image and copyright information in PMC

References

    1. Fung JJ, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK-506 vs. cyclosporine. Transplantation Proc. 1991;23:6, 2977–2983. - PMC - PubMed
    1. Starzl TE, Fung JJ, Jordan M, et al. Kidney transplantation under FK-506. JAMA. 1990;264:63–67. - PMC - PubMed
    1. Armitage JM, Kornos RL, Fung JJ, Starzl TE. The clinical trial of FK-506 as a primary and rescue immunosuppression in adult cardiac transplantation. Transplantation Proc. 1991;23:6, 3054–3057. - PMC - PubMed
    1. Griffith BP, Bando K, Hardesty RL, et al. Prospective randomized trial of FK-506 vs. cyclosporine. Presented at American Society of Transplant Surgeons Annual Meeting; 1993.
    1. Todo S, Tzakis A, Reyes J, et al. Clinical small bowel or small bowel plus liver transplantation under FK-506. Transplantation Proc. 1991;23(6):3093–3098. - PMC - PubMed

MeSH terms